Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...
Zacks Investment Research on MSN
EW wins FDA approval for SAPIEN M3 as first transseptal TMVR therapy
Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making ...
The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...
First-of-its-kind Edwards SAPIEN M3 transcatheter mitral valve system secures FDA approval for transseptal mitral ...
Transcatheter heart valve repair and replacement have reshaped how structural heart disease is treated, and the market is ...
Edwards Lifesciences (EW) announced on Tuesday that the U.S. Food and Drug Administration approved its SAPIEN M3 ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve ...
Edwards Lifesciences Corporation EW announced its decision to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company. This follows Edwards Lifescience ...
Edwards Lifesciences announced Thursday that the California company has completed three first-in-human implants of the company’s transcatheter mitral valve replacement system. But it is not the only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback